Curcugen® is a dispersible, clinically-studied, whole turmeric extract, delivering 39-times MORE curcuminoids to the plasma for diverse benefits and indications. As a next generation curcumin formula, Curcugen® is synergized by numerous turmeric-native actives, is food and beverage friendly, has been deemed GRAS (self-affirmed) by an expert panel and has been fully evaluated for safety, the results of which have been published and align to global standards.

 

 

 

Curcuminoids, turmeric essential oils and resins are naturally housed within the turmeric oleoresin. They are exclusively represented in Curcugen® and complemented by a diverse spectrum of other turmeric native compounds. Curcugen’s full-spectrum profile benefits from the strategic and patent-protected application of safe, food-grade solvents and precipitants.

Curcugen® is the only oleoresin-sourced turmeric active on the market to generate its absorption benefit from the dispersion power found in a previously ignored turmeric native – ‘polar’ resins.

Curcugen® uniquely delivers the same ratio of curcuminoid analogues – curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) – as found in the turmeric rhizome in its food state, or as its primary derivative, the oleoresin. While Curcugen® is concentrated to a 50% standard of curcuminoids, it is not hyper-purified, as is common with other curcuminoid formulations. Therein, Curcugen® retains a closely matched ratio of these cousin-molecules to what is natural, and found most familiarly in food.

In an 18-subject, cross-over pharmacokinetics study over 24-hours, Curcugen®, at 2000 mg of curcuminoids equivalents enhanced FREE-curcumin bioavailability by 39X that of placebo, and proved 52.5-times more bioavailable for Total Curcuminoids than standardized curcumin 95% (C-95).

Curcugen® is one of the first curcuminoids formulas to prove an increase in the bioavailability of endogenously-produced tetrahydrocurcumin (THC). THC is thought to be a more potent antioxidant than curcumin, although curcuminoid analogues appear to still offer more potent inflammatory signal modulation than THC. Curcugen® enhanced total THC bioavailability by 31X over C-95.

Curcugen’s efficacy is backed by several, published clinical studies in the dosage range of 500 – 1000 mg/day. The Curcugen study portfolio will continue to grow with additional clinical studies underway or in active peer review. Please contact our team for periodic updates.

Curcugen® is a suitable for a variety of formulations – traditional and novel food and beverage formats alike. Curcugen® is palate-friendly – requiring minimal flavoring and no masking, free flowing, highly dispersible and very stable. Many formulation concepts for Curcugen® have been explored, some of which include: